Targeting Cellular Immunity to Generate a Robust Antitumor Response

Biocytics’ diverse portfolio of cell therapy programs leverages the intrinsic specificity of autologous immune cells for the treatment of solid tumors. Current pipeline therapeutics are derived from lymphoid lineage cells including αβ T cells enriched for TAA-specific clones, memory NK cells, and γδ T cells. By developing products from different cell types we seek to maximize potential patient benefit based on tumor type, biomarkers, and immune infiltration in the TME.

Our discovery and pre-clinical development process is informed by three core principles: (1) Point-of-care collection, expansion, and formulation, (2) Inherent receptor specificity of autologous lymphocytes, and a (3) Proprietary ex-vivo culture system. Generating therapeutic products from different immune cell lineages allows our products to find and identify cancer cells in a pleiotropic manner. Rather than using a chimeric antigen receptor (CAR) with a single or dual specificity, BioCytics’ cellular fractions can broadly target cancer by recognition of mutated tumor peptides, phosphoantigens, HLA downregulation, and/or innate signals of cellular stress.

By administering individually or in combination TAA-specific aβ T cells, NK cells, and γδ T cells, in-vitro-expanded autologous immune cells may synergize to yield robust antitumor activity.

Our Pipeline

BioCytics is cultivating a pipeline of diverse therapies with an initial focus in Immuno-Oncology to bring the promise of adoptive cell therapy to solid tumor patients. We are actively seeking collaborations for the development of novel and combination therapies to address the unmet needs in Oncology.

*These products and their uses are investigational and have not been proven to be safe or been approved by the U.S. Food and Drug Administration (FDA).